Arcutis Biotherapeutics
ARQT
ARQT
167 hedge funds and large institutions have $1.24B invested in Arcutis Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 52 increasing their positions, 40 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
26% more funds holding
Funds holding: 133 → 167 (+34)
5.04% less ownership
Funds ownership: 113.75% → 108.71% (-5%)
42% less call options, than puts
Call options by funds: $6.39M | Put options by funds: $11.1M
Holders
167
Holding in Top 10
6
Calls
$6.39M
Puts
$11.1M
Top Buyers
| 1 | +$71.9M | |
| 2 | +$42M | |
| 3 | +$30.8M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$21.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$19M |
Top Sellers
| 1 | -$80.9M | |
| 2 | -$21.6M | |
| 3 | -$10.7M | |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$9.79M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$9.77M |